← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

OABI logoOmniAb, Inc.(OABI)Earnings, Financials & Key Ratios

OABI•NASDAQ
$1.47
$167M mkt cap·Price updated May 7, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryDrug Discovery and Antibody Platforms
AboutOmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.Show more
  • Revenue$19M-29.3%
  • EBITDA-$50M+2.3%
  • Net Income-$65M-4.4%
  • EPS (Diluted)-0.57+6.6%
  • Gross Margin-18.17%-118.2%
  • EBITDA Margin-266.6%-38.2%
  • Operating Margin-383.15%-35.7%
  • Net Margin-347.04%-47.6%
  • ROE-23.36%-13.4%
  • ROIC-19.68%-6.9%
  • Debt/Equity0.08-5.4%
Technical→

OABI Key Insights

OmniAb, Inc. (OABI) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Trading at only 0.6x book value

✗Weaknesses

  • ✗Profits declining 29.8% over 5 years
  • ✗Weak Piotroski F-Score: 2/9
  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 19 (bottom 19%)
  • ✗Shares diluted 11.0% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

OABI Price & Volume

OmniAb, Inc. (OABI) stock price & volume — 10-year historical chart

Loading chart...

OABI Growth Metrics

OmniAb, Inc. (OABI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-4.31%
3 Years-31.89%
TTM8.21%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM11.4%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM20.69%

Return on Capital

10 Years-14.31%
5 Years-17.11%
3 Years-21.7%
Last Year-24.03%

OABI Recent Earnings

OmniAb, Inc. (OABI) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
Mar 4, 2026
EPS
$0.11
Est $0.08
-37.5%
Revenue
$8M
Est $9M
-7.0%
Q4 2025
Nov 4, 2025
EPS
$0.14
Est $0.14
-2.9%
Revenue
$2M
Est $6M
-60.3%
Q3 2025
Aug 6, 2025
EPS
$0.15
Est $0.14
-7.1%
Revenue
$4M
Est $6M
-31.0%
Q2 2025
May 8, 2025
EPS
$0.17
Est $0.17
+0.0%
Revenue
$4M
Est $4M
-7.5%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMar 4, 2026
$0.11vs $0.08-37.5%
$8Mvs $9M-7.0%
Q4 2025Nov 4, 2025
$0.14vs $0.14-2.9%
$2Mvs $6M-60.3%
Q3 2025Aug 6, 2025
$0.15vs $0.14-7.1%
$4Mvs $6M-31.0%
Q2 2025May 8, 2025
$0.17vs $0.17+0.0%
$4Mvs $4M-7.5%
Based on last 12 quarters of dataView full earnings history →

OABI Peer Comparison

OmniAb, Inc. (OABI) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
HALO logoHALOHalozyme Therapeutics, Inc.Direct Competitor7.68B65.1925.4637.55%22.69%6.49%
ADCT logoADCTADC Therapeutics S.A.Direct Competitor478.24M3.76-3.3614.85%-173.02%
RCUS logoRCUSArcus Biosciences, Inc.Direct Competitor2.5B24.80-7.54-4.26%-156.36%-68.97%0.16
IMVT logoIMVTImmunovant, Inc.Direct Competitor5.53B27.22-9.97-47.07%0.00
REGN logoREGNRegeneron Pharmaceuticals, Inc.Product Competitor73.68B709.1017.100.99%29.65%14.32%0.09
ABCL logoABCLAbCellera Biologics Inc.Product Competitor1.45B4.82-9.84160.56%-194.89%-15.14%0.14
TWST logoTWSTTwist Bioscience CorporationProduct Competitor3.65B58.54-45.0320.32%-19.85%-17.46%0.29
SEER logoSEERSeer, Inc.Product Competitor104.88M1.88-1.35-8.13%-486.02%-29.19%0.08

Compare OABI vs Peers

OmniAb, Inc. (OABI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HALO

Most directly comparable listed peer for OABI.

Scale Benchmark

vs TMO

Larger-name benchmark to compare OABI against a more recognizable public peer.

Peer Set

Compare Top 5

vs HALO, ADCT, RCUS, IMVT

OABI Income Statement

OmniAb, Inc. (OABI) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue18.32M23.27M34.75M59.08M34.16M26.39M18.67M28.94M
Revenue Growth %-27.02%49.34%70.02%-42.17%-22.75%-29.27%8.21%
Cost of Goods Sold00000022.06M4.97M
COGS % of Revenue------118.17%-
Gross Profit
18.32M▲ 0%
23.27M▲ 27.0%
34.75M▲ 49.3%
59.08M▲ 70.0%
34.16M▼ 42.2%
26.39M▼ 22.8%
-3.39M▼ 112.8%
23.97M▲ 0%
Gross Margin %100%100%100%100%100%100%-18.17%82.83%
Gross Profit Growth %-27.02%49.34%70.02%-42.17%-22.75%-112.85%-
Operating Expenses31.34M48.89M70.36M85.72M103.58M100.89M68.13M74.12M
OpEx % of Revenue171.12%210.12%202.48%145.11%303.19%382.3%364.98%-
Selling, General & Admin8.65M10.22M16.95M24.9M33.31M30.74M29.21M26.49M
SG&A % of Revenue47.23%43.94%48.77%42.15%97.51%116.48%156.51%-
Research & Development13.21M24.8M39.23M48.36M56.52M55.11M47.75M44.79M
R&D % of Revenue72.1%106.57%112.9%81.87%165.45%208.82%255.83%-
Other Operating Expenses9.49M13.87M14.18M12.46M13.74M15.04M-8.84M1.01M
Operating Income
-13.03M▲ 0%
-25.62M▼ 96.7%
-35.61M▼ 39.0%
-26.65M▲ 25.2%
-69.42M▼ 160.5%
-74.5M▼ 7.3%
-71.52M▲ 4.0%
-50.07M▲ 0%
Operating Margin %-71.12%-110.12%-102.48%-45.11%-203.19%-282.3%-383.15%-173.02%
Operating Income Growth %--96.69%-38.97%25.16%-160.5%-7.32%4.01%-
EBITDA-2.43M-13M-19.36M-8.4M-49.92M-50.92M-49.76M-33.06M
EBITDA Margin %-13.29%-55.85%-55.71%-14.22%-146.12%-192.94%-266.6%-114.24%
EBITDA Growth %--433.94%-48.95%56.61%-494.38%-2%2.27%30.28%
D&A (Non-Cash Add-back)10.59M12.63M16.25M18.25M19.5M23.58M21.75M17.01M
EBIT-13.85M-23.55M-34.34M-26.65M-69.42M-74.5M-71.52M-50.23M
Net Interest Income0-5K-7K587K5.05M3.11M2.66M2.12M
Interest Income000587K5.05M3.11M2.66M2.61M
Interest Expense05K7K00000
Other Income/Expense01.9M1.26M587K5.06M3.09M5.22M-2.86M
Pretax Income
-13.03M▲ 0%
-23.73M▼ 82.1%
-34.35M▼ 44.8%
-26.06M▲ 24.1%
-64.36M▼ 147.0%
-71.41M▼ 11.0%
-66.29M▲ 7.2%
-52.93M▲ 0%
Pretax Margin %-71.12%-101.98%-98.85%-44.11%-188.39%-270.59%-355.16%-182.91%
Income Tax562K-6.17M-7.31M-3.73M-13.74M-9.38M-1.51M471K
Effective Tax Rate %-4.31%26.01%21.28%14.3%21.35%13.13%2.29%-0.89%
Net Income
-13.59M▲ 0%
-17.56M▼ 29.2%
-27.04M▼ 54.0%
-22.33M▲ 17.4%
-50.62M▼ 126.6%
-62.03M▼ 22.5%
-64.78M▼ 4.4%
-54.29M▲ 0%
Net Margin %-74.18%-75.46%-77.82%-37.8%-148.16%-235.05%-347.04%-187.59%
Net Income Growth %--29.2%-54.02%17.41%-126.65%-22.55%-4.43%11.4%
Net Income (Continuing)-13.59M-17.56M-27.04M-22.33M-50.62M-62.03M-64.78M-54.29M
Discontinued Operations00000000
Minority Interest00000000
EPS (Diluted)
-0.12▲ 0%
-0.15▼ 25.0%
-0.24▼ 60.0%
-0.26▼ 8.3%
-0.51▼ 96.2%
-0.61▼ 19.6%
-0.57▲ 6.6%
-0.42▲ 0%
EPS Growth %--25%-60%-8.33%-96.15%-19.61%6.56%20.69%
EPS (Basic)-0.12-0.15-0.24-0.26-0.51-0.61-0.57-
Diluted Shares Outstanding114.82M114.82M114.82M85.32M99.68M102.36M113.64M128.25M
Basic Shares Outstanding114.82M114.82M114.82M85.32M99.68M102.36M113.64M128.25M
Dividend Payout Ratio--------

OABI Balance Sheet

OmniAb, Inc. (OABI) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets7.79M16.65M22.54M124.95M94.9M68.14M65.34M65.13M
Cash & Short-Term Investments00088.27M86.98M59.43M54.02M49.07M
Cash Only00033.39M16.36M27.6M25.52M29.05M
Short-Term Investments00054.88M70.63M31.84M28.5M20.03M
Accounts Receivable7.77M15.88M21.14M30.29M3.84M5.27M7.39M12.64M
Days Sales Outstanding154.9249.03222.02187.1441.0772.91144.5181.45
Inventory00000000
Days Inventory Outstanding--------
Other Current Assets21K774K1.41M6.39M4.07M3.43M3.93M3.41M
Total Non-Current Assets254.53M278.73M281.92M296.26M280.32M257.42M235.57M228.53M
Property, Plant & Equipment4.32M5.98M20.13M41.46M38.13M33.28M24.97M24.07M
Fixed Asset Turnover4.24x3.89x1.73x1.42x0.90x0.79x0.75x1.06x
Goodwill77.11M83.98M83.98M83.98M83.98M83.98M83.98M83.98M
Intangible Assets172.98M186.64M176.32M167.24M155.47M138.06M125.15M119.12M
Long-Term Investments0000000560K
Other Non-Current Assets115K2.13M1.5M3.58M2.75M2.1M1.47M5.58M
Total Assets
262.32M▲ 0%
295.38M▲ 12.6%
304.46M▲ 3.1%
421.21M▲ 38.3%
375.23M▼ 10.9%
325.56M▼ 13.2%
300.91M▼ 7.6%
293.65M▲ 0%
Asset Turnover0.07x0.08x0.11x0.14x0.09x0.08x0.06x0.10x
Asset Growth %-12.6%3.08%38.34%-10.92%-13.24%-7.57%-30.59%
Total Current Liabilities6.14M14.28M20.58M26.02M23.12M15.09M16.25M13.57M
Accounts Payable806K469K2.92M2.97M4.41M2.3M1.88M1.65M
Days Payables Outstanding------31.09136.16
Short-Term Debt0000003.88M3.94M
Deferred Revenue (Current)07.16M10.79M8.21M6.85M2.34M3.16M8.72M
Other Current Liabilities4.55M3.79M4.92M8.18M7.8M6.67M7.33M6.68M
Current Ratio1.27x1.17x1.10x4.80x4.11x4.52x4.02x4.02x
Quick Ratio1.27x1.17x1.10x4.80x4.11x4.52x4.02x4.02x
Cash Conversion Cycle--------54.71
Total Non-Current Liabilities38M45.57M49.58M53.82M37.52M22.85M17.63M17.44M
Long-Term Debt000000015.73M
Capital Lease Obligations2.27M2.01M13.27M24.02M22.07M19.38M16.45M51.6M
Deferred Tax Liabilities028.93M21.96M21.34M11.35M2.31M785K5.5M
Other Non-Current Liabilities35.72M6.4M5.12M4.13M3.23M1.04M393K2.13M
Total Liabilities44.13M59.84M70.16M79.84M60.64M37.94M33.89M31M
Total Debt2.58M2.59M13.85M25.8M25.56M23.16M20.33M19.67M
Net Debt2.58M2.59M13.85M-7.59M9.2M-4.43M-5.19M-9.38M
Debt / Equity0.01x0.01x0.06x0.08x0.08x0.08x0.08x0.08x
Debt / EBITDA--------0.59x
Net Debt / EBITDA-------0.28x
Interest Coverage--4710.60x-4906.14x-----
Total Equity
218.19M▲ 0%
235.54M▲ 8.0%
234.31M▼ 0.5%
341.37M▲ 45.7%
314.58M▼ 7.8%
287.62M▼ 8.6%
267.03M▼ 7.2%
262.65M▲ 0%
Equity Growth %-7.95%-0.52%45.69%-7.85%-8.57%-7.16%-26.95%
Book Value per Share1.902.052.044.003.162.812.352.05
Total Shareholders' Equity218.19M235.54M234.31M341.37M314.58M287.62M267.03M262.65M
Common Stock218.19M0012K12K12K14K14K
Retained Earnings00011.25M-39.37M-101.4M-166.18M-173.89M
Treasury Stock00000000
Accumulated OCI0009K50K27K12K-2K
Minority Interest00000000

OABI Cash Flow Statement

OmniAb, Inc. (OABI) cash flow — operating, investing & free cash flow history

Line itemDec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations-5.2M3.62M-5.67M-3.59M2.35M-39.66M-36.45M-36.45M
Operating CF Margin %-28.36%15.55%-16.32%-6.07%6.87%-150.29%-195.3%-
Operating CF Growth %-169.66%-256.73%36.76%165.43%-1789.99%8.09%31.84%
Net Income-13.59M-17.56M-27.04M-22.33M-50.62M-62.03M-64.78M-54.29M
Depreciation & Amortization10.92M13.14M16.25M18.25M19.5M23.58M21.75M23.64M
Stock-Based Compensation6.66M9.16M15.06M18.32M24.82M21.5M15.82M11.06M
Deferred Taxes557K-6.18M-7.33M-6.42M-12.54M-9.04M0-1.27M
Other Non-Cash Items-818K331K9K-572K-3.68M-3.5M-4.3M-5.1M
Working Capital Changes-8.92M4.73M-2.63M-10.83M24.87M-10.17M-4.95M449K
Change in Receivables-4.29M339K6.02M-12.74M26.9M-625K189K-4.26M
Change in Inventory00-1.51M00000
Change in Payables001.51M15.07M920K-2.41M-231K215K
Cash from Investing-12.1M-26.98M-4.03M-73.31M-18.38M37.88M6.47M15.78M
Capital Expenditures-255K-1.75M-4.07M-17.17M-1.64M-1.88M-565K-523K
CapEx % of Revenue1.39%7.53%11.71%29.06%4.81%7.1%3.03%-
Acquisitions-11.84M-27.13M000000
Investments--------
Other Investing01.9M-1.22M-1.44M-4.44M-400K3M3M
Cash from Financing17.29M23.36M9.7M110.74M-892K13.02M27.91M27.87M
Debt Issued (Net)00000000
Equity Issued (Net)00096.24M011.37M28.36M28.32M
Dividends Paid00000000
Share Repurchases00000000
Other Financing17.29M23.36M9.7M14.5M-892K1.65M-450K-450K
Net Change in Cash
0▲ 0%
0▲ 0%
0▲ 0%
33.84M▲ 0%
-16.92M▼ 150.0%
11.24M▲ 166.4%
-2.07M▼ 118.5%
18.15M▲ 0%
Free Cash Flow
-5.45M▲ 0%
1.87M▲ 134.2%
-9.74M▼ 622.1%
-20.75M▼ 113.0%
703K▲ 103.4%
-41.54M▼ 6008.8%
-37.02M▲ 10.9%
-26.02M▲ 0%
FCF Margin %-29.75%8.02%-28.04%-35.13%2.06%-157.4%-198.33%-89.91%
FCF Growth %-134.24%-622.08%-113.05%103.39%-6008.82%10.88%34.4%
FCF per Share-0.050.02-0.08-0.240.01-0.41-0.33-0.33
FCF Conversion (FCF/Net Income)0.38x-0.21x0.21x0.16x-0.05x0.64x0.56x0.48x
Interest Paid00000000
Taxes Paid00002.61M16K00

OABI Key Ratios

OmniAb, Inc. (OABI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric202020212022202320242025TTM
Return on Equity (ROE)-7.74%-11.51%-7.76%-15.43%-20.6%-23.36%-20.31%
Return on Invested Capital (ROIC)-8.38%-10.98%-6.87%-15.84%-18.41%-19.68%-19.68%
Gross Margin100%100%100%100%100%-18.17%82.83%
Net Margin-75.46%-77.82%-37.8%-148.16%-235.05%-347.04%-187.59%
Debt / Equity0.01x0.06x0.08x0.08x0.08x0.08x0.08x
Interest Coverage-4710.60x-4906.14x-----
FCF Conversion-0.21x0.21x0.16x-0.05x0.64x0.56x0.48x
Revenue Growth27.02%49.34%70.02%-42.17%-22.75%-29.27%8.21%

OABI SEC Filings & Documents

OmniAb, Inc. (OABI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Mar 4, 2026·SEC

Material company update

Jan 30, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 4, 2026·SEC

FY 2025

Mar 18, 2025·SEC

FY 2024

Mar 25, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2025

Nov 4, 2025·SEC

FY 2025

Aug 6, 2025·SEC

OABI Frequently Asked Questions

OmniAb, Inc. (OABI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

OmniAb, Inc. (OABI) reported $28.9M in revenue for fiscal year 2025. This represents a 58% increase from $18.3M in 2019.

OmniAb, Inc. (OABI) saw revenue decline by 29.3% over the past year.

OmniAb, Inc. (OABI) reported a net loss of $54.3M for fiscal year 2025.

Dividend & Returns

OmniAb, Inc. (OABI) has a return on equity (ROE) of -23.4%. Negative ROE indicates the company is unprofitable.

OmniAb, Inc. (OABI) had negative free cash flow of $26.0M in fiscal year 2025, likely due to heavy capital investments.

Explore More OABI

OmniAb, Inc. (OABI) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.